Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28868791 | 0.94 | LMNA (0.45) | LMNAKDM1APTPN1MEN1CYP3A4 | |
| SCHEMBL6990184 | 0.92 | LMNA (0.46) | LMNA | |
| SCHEMBL971387 | 0.88 | LMNA (0.48) | LMNAKDM1APTPN1MEN1CYP3A4 | |
| SCHEMBL7995031 | 0.87 | LMNA (0.35) | LMNA | |
| SCHEMBL286602 | 0.86 | LMNA (0.46) | LMNA | |
| SCHEMBL1164744 | 0.83 | LMNA (0.38) | LMNA | |
| SCHEMBL9132313 | 0.83 | TSHR (0.38) | LMNA | |
| SCHEMBL2999056 | 0.83 | TSHR (0.38) | LMNA | |
| SCHEMBL9366046 | 0.83 | LMNA (0.39) | LMNA | |
| SCHEMBL7067432 | 0.82 | LMNA (0.48) | LMNAKDM1APTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2942348-B1 | Thiol-protected amino acid derivatives and uses thereof | Johannes Gutenberg-Universität Mainz (DE) | 2017-10-25 | — | — | EP | claimed |
| US-9882245-B2 | Alkoxide-based magnesium electrolyte compositions for magnesium batteries | UT-BATTELLE, LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160024421-A1 | IONIC LIQUIDS CONTAINING QUATERNARY PHOSPHONIUM CATIONS AND CARBOXYLATE ANIONS, AND THEIR USE AS LUBRICANT ADDITIVES | U.S. DEPARTMENT OF ENERGY | 2016-01-28 | — | — | US | disclosed |
| US-9149479-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-20150056499-A1 | ALKOXIDE-BASED MAGNESIUM ELECTROLYTE COMPOSITIONS FOR MAGNESIUM BATTERIES | U.S. DEPARTMENT OF ENERGY | 2015-02-26 | — | — | US | disclosed |
| US-20150024037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | THE UNIVERSITY OF TOLEDO (US) | 2015-01-22 | — | — | US | disclosed |
| US-8557991-B2 | Process for preparing enantiomerically pure indolopyridines | 4SC AG (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8288399-B2 | Medicine containing pyrimidine derivative | BTG INTERNATIONAL LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| EP-2420489-A1 | Indolesulfonyl protecting groups for protection of guanidino and amino groups | Lonza Ltd (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20120018676-A1 | Novel Tricyanoborates | LONZA LTD. (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-1999057118-A1 | NOVEL N-OXIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999057115-A1 | NOVEL BENZIMIDAZOLES AND BENZOXAZOLES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-11-11 | — | — | WO | disclosed |
| US-5786488-A | DEHYDROBROMINATION OF A DIBROMOBENZOQUINONES WITH AT LEAST ONE INDOLES IN A POLAR SOLVENT AND A METAL CARBONATE TO FORM AN ANTITUMOR AGENT | SUGEN, INC. (US) | 1998-07-28 | — | — | US | disclosed |
| US-5747539-A | Fluorine-containing benzoylguanidines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-05-05 | — | — | US | disclosed |
| EP-0228959-B1 | AMINOSTYRYL COMPOUND, LEUKOTRIENE ANTAGONISTIC COMPOSITION CONTAINING THE SAME AS EFFECTIVE INGREDIENTS AND METHOD OF ANTAGONIZING SRS BY EMPLOYING THE SAME | MITSUBISHI KASEI CORPORATION (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4749701-A | Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1988-06-07 | — | — | US | disclosed |
| EP-0228959-A2 | Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same | MITSUBISHI KASEI CORPORATION (JP) | 1987-07-15 | — | — | EP | disclosed |
| US-4338315-A | RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4288361-A | ANTIOXIDANTS FOR POLYMERS | CARSTAB CORPORATION (US) | 1981-09-08 | — | — | US | disclosed |
| US-4205176-A | ANTIOXIDANTS | CINCINNATI MILACRON CHEMICALS INC. (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120018676-A1 | Novel Tricyanoborates | XRN2, XRCC6, CNOT1 | LMNA 734/4885KDM1A 969/4885PTPN1 3760/4885 |
| US-20150024037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | CSGALNACT1, GALNT1, DPAGT1 | LMNA 1554/4885KDM1A 397/4885PTPN1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.